Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.

[1]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[2]  G. Fonarow,et al.  The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. , 2003, Reviews in cardiovascular medicine.

[3]  C. Yancy,et al.  Variation in heart failure quality of care indicators among U.S. hospitals: analysis of 230 hospitals in the ADHERE registry , 2003 .

[4]  K. Swedberg,et al.  &bgr;-Blockers in Chronic Heart Failure , 2003, Circulation.

[5]  J. Rouleau,et al.  Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. , 2003, JAMA.

[6]  R. Allman,et al.  Age-Related Underutilization of Angiotensin-Converting Enzyme Inhibitors in Older Hospitalized Heart Failure Patients , 2002, Southern medical journal.

[7]  D. Moser,et al.  Improving outcomes in heart failure: It's not unusual beyond usual care. , 2002, Circulation.

[8]  M. Fisher,et al.  Tolerability of &bgr;-Blocker Initiation and Titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) , 2002, Circulation.

[9]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[10]  G. Fonarow.  Clinical diagnosis and prognosis of acute limb ischemia. , 2002 .

[11]  C. O'connor,et al.  The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications. , 2002, Reviews in cardiovascular medicine.

[12]  C. O'connor,et al.  The benefit of implementing a heart failure disease management program. , 2001, Archives of internal medicine.

[13]  G. Fonarow,et al.  In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. , 2001, Circulation.

[14]  A. Gawlinski,et al.  Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). , 2001, The American journal of cardiology.

[15]  John Wikstrand,et al.  Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) , 2000 .

[16]  W. Rogers,et al.  Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. , 2000, Journal of the American College of Cardiology.

[17]  A. Dilenarda,et al.  [Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure]. , 2000, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[18]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[19]  A. Gawlinski,et al.  Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. , 2000, The American journal of cardiology.

[20]  M. Packer,et al.  Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure. , 1999, The American journal of cardiology.

[21]  C B Granger,et al.  Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. , 1999, European heart journal.

[22]  N. Every,et al.  A comparison of the national registry of myocardial infarction 2 with the cooperative cardiovascular project. , 1999, Journal of the American College of Cardiology.

[23]  Thomas D. Giles,et al.  Consensus recommendations for the management of chronic heart failure: Introduction , 1999 .

[24]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[25]  Marvin A. Konstam,et al.  Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. , 1999, Journal of cardiac failure.

[26]  M. G. Levine,et al.  Functional assessment with electrocardiographic gated single-photon emission computed tomography improves the ability of technetium-99m sestamibi myocardial perfusion imaging to predict myocardial viability in patients undergoing revascularization. , 1999, The American journal of cardiology.

[27]  G. Fonarow,et al.  Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. , 1997, Journal of the American College of Cardiology.

[28]  C M Ashton,et al.  The Association between the Quality of Inpatient Care and Early Readmission , 1995, Annals of Internal Medicine.

[29]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[30]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.